Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA

Experts discuss proactive steps health care teams, including pharmacists, can take to minimize delays and overcome payer-related barriers when prescribing third-line therapies for metastatic colorectal cancer (mCRC) and how collaboration between health care teams, payers, and manufacturers can be improved to reduce care delays.

Experts discuss effective strategies for navigating the prior authorization process to ensure timely access to third-line therapies for metastatic colorectal cancer (mCRC) and share any success stories.

Experts discuss key payer-related challenges, such as step edits and prior authorizations, that impact access to third-line therapies for patients with metastatic colorectal cancer (mCRC). They also discuss how payer requirements influence treatment sequencing and decision-making in the third-line setting and how the costs associated with adverse events across different third-line treatments affect treatment selection.

Experts discuss how pharmacists contribute to managing adverse events and toxicity for patients undergoing metastatic colorectal cancer (mCRC) treatment. They explore the factors influencing patient adherence to third-line therapies and ways pharmacists can improve patient education to enhance adherence to treatment regimens.

Experts discuss how the role of oncology pharmacists in managing metastatic colorectal cancer (mCRC) has evolved, particularly in enabling medication adjustments, refills, and prescribing supportive care medications, and explore the impact of this expanded role on patient outcomes and how pharmacists can leverage medication knowledge to optimize treatment and patient care further.

Experts discuss the typical patient journey for an individual with metastatic colorectal cancer (mCRC), highlighting where pharmacists participate in the process. They also explore how pharmacists collaborate with oncologists and other multidisciplinary team members to provide comprehensive care for patients with mCRC.

Experts discuss additional factors considered when determining the most effective sequence of therapies for metastatic colorectal cancer, including fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab, and explore the further research needed to understand optimal sequencing of these treatments better.

Experts discuss practical strategies used by their institutions to manage treatment-related toxicities with third-line therapies for metastatic colorectal cancer (mCRC) and share their experiences on how third-line therapy options have impacted patients’ quality of life.

Experts discuss how they balance safety, efficacy, and overall patient prognosis when selecting third-line treatments for metastatic colorectal cancer (mCRC) and explore how the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, informing treatment decisions.

Experts provide an overview of third-line treatment options for metastatic colorectal cancer (mCRC) in patients with disease progression through all available regimens, focusing on fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab.